P7C3

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H18Br2N2O
Molecular Weight	474.188
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(CNC1=CC=CC=C1)CN2C3=C(C=C(Br)C=C3)C4=C2C=CC(Br)=C4

InChI

InChIKey=FZHHRERIIVOATI-UHFFFAOYSA-N

InChI=1S/C21H18Br2N2O/c22-14-6-8-20-18(10-14)19-11-15(23)7-9-21(19)25(20)13-17(26)12-24-16-4-2-1-3-5-16/h1-11,17,24,26H,12-13H2

HIDE SMILES / InChI

Molecular Formula	C21H18Br2N2O
Molecular Weight	474.188
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23027934 | https://www.ncbi.nlm.nih.gov/pubmed/20603013

P7C3 is a chemical compound belongs to a class of proneurogenic compounds that are potential nicotinamide phosphoribosyltransferase (NAMPT) activators, and might shed light on future drug development in neurogenesis restoration. This compound protects newborn neurons in the dentate gyrus by mitigating cell death. Also enhances learning and memory in aged rats. In addition on animal models was shown, that P7C3 is sufficient to restore the neurogenic deficits observed in the Ts65Dn mouse model of Down Syndrome, and also was discovered, that P7C3 might provide a basis for the discovery and optimization of pharmacologic agents for the treatment of amyotrophic lateral sclerosis (ALS) and for the treatment of patients with Parkinson disease (PD).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Nicotinamide phosphoribosyltransferase 8 Target ID: CHEMBL1744525 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25215490	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Down syndrome 6 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25668489	Primary	Phase I 438	Unknown Approved Use Unknown
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23027934	Primary	Preclinical	Unknown Approved Use Unknown
Amyotrophic lateral sclerosis 39 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23027932	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.	2014-09-11	25215490
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.	2012-10-16	23027934
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis.	2012-10-16	23027932
Discovery of a proneurogenic, neuroprotective chemical.	2010-07-09	20603013

Patents

Sample Use Guides

In Vivo Use Guide

in rats: 10mg/ kg of P7C3 in mice: P7C3 was 32% orally bioavailable and endowed with a plasma terminal half life of 6.7 hours after IP delivery. Daily oral administration of P7C3 for seven days to adult mice was monitored for brain levels of the chemical and pro-neurogenic efficacy. Maximal, pro-neurogenic efficacy was observed at oral doses of 5mg/ kg and above, and graded reductions in efficacy were observed at doses of 2.5 and 1mg/ kg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:13:15 GMT 2025` Edited by `admin` on `Wed Apr 02 09:13:15 GMT 2025`
Record UNII	77ZWJ3QXR9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

P7C3

Common Name

English

1-(3,6-DIBROMO-CARBAZOL-9-YL)-3-PHENYLAMINO-PROPAN-2-OL

Preferred Name

English

9H-CARBAZOLE-9-ETHANOL, 3,6-DIBROMO-.ALPHA.-((PHENYLAMINO)METHYL)-

Systematic Name

English

3,6-DIBROMO-.ALPHA.-((PHENYLAMINO)METHYL)-9H-CARBAZOLE-9-ETHANOL

Systematic Name

English

1-ANILINO-3-(3,6-DIBROMOCARBAZOL-9-YL)PROPAN-2-OL

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID70385472